Literature DB >> 20832121

Endothelial cell loss and visual outcome of deep anterior lamellar keratoplasty versus penetrating keratoplasty: a randomized multicenter clinical trial.

Yanny Y Y Cheng1, Nienke Visser, Jan S Schouten, Robert-Jan Wijdh, Elisabeth Pels, Hugo van Cleynenbreugel, Catharina A Eggink, Michel J W Zaal, Wilhelmina J Rijneveld, Rudy M M A Nuijts.   

Abstract

OBJECTIVE: To compare endothelial cell (EC) loss, visual and refractive outcomes, and complications after deep anterior lamellar keratoplasty (DALK) and penetrating keratoplasty (PK).
DESIGN: Randomized, multicenter clinical trial. PARTICIPANTS: Fifty-six eyes of 56 patients with a corneal stromal pathology not affecting the endothelium were randomized to DALK or PK.
METHODS: The DALK procedure was performed according to Anwar's big-bubble technique. Patients underwent an ophthalmic examination preoperatively and 3, 6, and 12 months postoperatively. MAIN OUTCOME MEASURES: Endothelial cell loss, refractive and topographic astigmatism, spherical equivalent, uncorrected visual acuity, and best spectacle-corrected visual acuity (BSCVA) were measured, and complications were recorded.
RESULTS: Endothelial cell loss was significantly higher after PK compared with DALK procedures performed without perforation of Descemet's membrane (12 months: 27.7% ± 11.1% vs. 12.9% ± 17.6%). The BSCVA was significantly better in the PK group at 3 and 6 months after surgery but was not significantly different 12 months after surgery (0.39 ± 0.3 logarithm of the minimum angle of resolution [logMAR] in DALK and 0.31 ± 0.3 logMAR in PK). At 12 months postoperatively, refractive and topographic astigmatism in the DALK and PK groups were -3.37 ± 2.3 diopters (D) and -3.76 ± 2.1 D (P = 0.53), and 3.57 ± 2.3 D and 4.16 ± 2.0 D (P = 0.34), respectively. (Micro)perforation of the Descemet's membrane occurred in 32% (9/28) of the DALK eyes, and 18% (5/28) of the patients required conversion to PK. Endothelial cell loss was not significantly different between DALK and PK when cases with perforation of Descemet's membrane were included in the (intention-to-treat) analysis (12 months: 19.1 ± 21.6 vs. 27.7 ± 11.1 P = 0.112). Rejection episodes were reported in 1 patient in the DALK group (epithelial rejection) and 3 patients in the PK group (all endothelial rejections). No graft failure occurred.
CONCLUSIONS: One year after DALK performed without perforation of Descemet's membrane, EC loss is significantly lower, whereas the BSCVA is comparable to that in the PK group. In addition, no endothelial rejection occurred in the DALK group. However, Descemet's membrane perforation remains a major complication in DALK and warrants improvements to standardize the big-bubble technique.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20832121     DOI: 10.1016/j.ophtha.2010.06.005

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  32 in total

1.  Glaucoma in penetrating keratoplasty: risk factors, management and outcome.

Authors:  Klaudia K Huber; Anna-Karina B Maier; Matthias K J Klamann; Jessica Rottler; Sevil Özlügedik; Katja Rosenbaum; Johannes Gonnermann; Sibylle Winterhalter; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-30       Impact factor: 3.117

2.  Comparison of refractive outcomes in three corneal transplantation techniques for keratoconus.

Authors:  Ting Huang; Yunwei Hu; Mengru Gui; Chao Hou; Hong Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-08-14       Impact factor: 3.117

3.  Bilateral cloudy cornea: is the usual suspect congenital hereditary endothelial dystrophy or stromal dystrophy?

Authors:  Banu Torun Acar; Kansu Tahir Bozkurt; Erkan Duman; Suphi Acar
Journal:  BMJ Case Rep       Date:  2016-04-22

4.  Comparison of the effects of femtosecond laser energy on corneal endothelium at two different dissection levels in femtosecond laser-assisted deep anterior lamellar keratoplasty for keratoconus.

Authors:  Mustafa Saber Hafez; Ismail Hamza; Walid Mohamed El-Zawahry; Ashraf Hassan Soliman
Journal:  Int Ophthalmol       Date:  2021-01-05       Impact factor: 2.031

5.  Comparison of outcomes and complications of deep anterior lamellar keratoplasty and penetrating keratoplasty performed in a large group of patients with keratoconus.

Authors:  Ashbala Khattak; Fouad R Nakhli; Khaled M Al-Arfaj; Abdullah A Cheema
Journal:  Int Ophthalmol       Date:  2017-05-22       Impact factor: 2.031

6.  Corneal radius of curvature after anterior lamellar versus penetrating keratoplasty.

Authors:  Vincent M Borderie; Cristina Georgeon; Marie Borderie; Nacim Bouheraoua; Olivier Touzeau; Laurent Laroche
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-12-14       Impact factor: 3.117

7.  Therapeutic effect of deep anterior lamellar keratoplasty for active or quiescent herpetic stromal keratitis.

Authors:  Junyi Wang; Ge Zhao; Lixin Xie; Min Chen; Jing Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-17       Impact factor: 3.117

8.  Intraocular Pressure and Big Bubble Diameter in Deep Anterior Lamellar Keratoplasty: An Ex-Vivo Microscope-Integrated OCT With Heads-Up Display Study.

Authors:  Paramjit K Bhullar; Oscar M Carrasco-Zevallos; Alexandria Dandridge; Neel D Pasricha; Brenton Keller; Liangbo Shen; Joseph A Izatt; Cynthia A Toth; Anthony N Kuo
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2017 Sep-Oct

Review 9.  [Perspectives of deep anterior lamellar keratoplasty].

Authors:  C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

10.  Needle Depth and Big-Bubble Success in Deep Anterior Lamellar Keratoplasty: An Ex Vivo Microscope-Integrated OCT Study.

Authors:  Neel D Pasricha; Christine Shieh; Oscar M Carrasco-Zevallos; Brenton Keller; David Cunefare; Jodhbir S Mehta; Sina Farsiu; Joseph A Izatt; Cynthia A Toth; Anthony N Kuo
Journal:  Cornea       Date:  2016-11       Impact factor: 2.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.